FOLFOX-4

Phase 3Small molecule

Amgen

FOLFOX-4 is one of 104 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

FOLFOX-4

Amgen

Phase 3

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Vascepa

1 6

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 7

Ketalar

AAultman Health Foundation

Preclinical

1 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

Completed· Roche logo

Roche·Phase 3·NCT00349336·64 enrolled

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Completed· Amgen logo

Amgen·Phase 1·NCT00101894·119 enrolled

Liver Metastases2 trials

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

Completed· Amgen logo

Amgen·Phase 2·NCT00866944·35 enrolled

Intensified Chemotherapy in CRC After Resection of Liver Metastases

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2/3·NCT00208260·124 enrolled

Gastroesophageal Junction Cancer1 trial

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 3·NCT02934464·280 enrolled

Esophageal Cancer1 trial

Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00160030·97 enrolled

Colorectal Cancer1 trial

Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT00202787·136 enrolled

1 more indication

Metastatic1 trial

Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients

Completed·GGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente·Phase 3·NCT01030042·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for FOLFOX-4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX-4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX-4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Amgen

FOLFOX-4

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Liver Metastases2 trials

Gastroesophageal Junction Cancer1 trial

Esophageal Cancer1 trial

Colorectal Cancer1 trial

Metastatic1 trial

References

Drug Info

Quick Facts

Related News